The popularity of copyright’s blockbuster initially sparked a boom for pharma, but recent shifts present a uncertain scenario for shareholders. Off-patent versions are eroding profits, and continued litigation add https://philipbpcn513406.techionblog.com/41422431/sildenafil-and-big-pharma-a-volatile-bet